Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study

Arlindo R. Ferreira,A. Palha,L. Correia,P Filipe,Vasco Rodrigues,Ana Miranda,R. André,João Fernandes,J. Gouveia,J.L. Passos-Coelho,A. Moreira,Margarida Brito,J. Ribeiro,Otto Metzger Filho,Nan Lin,Luis Costa,Ines Vaz-Luis

Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study

2018

Arlindo R. Ferreira
A. Palha
L. Correia
P Filipe
Vasco Rodrigues
Ana Miranda
R. André
João Fernandes
J. Gouveia
J.L. Passos-Coelho
A. Moreira
Margarida Brito
J. Ribeiro
Otto Metzger Filho
Nan Lin
Luis Costa
Ines Vaz-Luis

• In HR+ breast cancer, randomized trials showed that: 1) adjuvant tamoxifen improved OS over no adjuvant endocrine therapy, and 2) adjuvant AI improved OS over tamoxifen. After 2005, AIs were recommended for postmenopausal women with HR+ BC.

Keywords:

Aromatase
Randomized controlled trial
Breast cancer
Gynecology
Tamoxifen
Medicine
Observational study
Retrospective cohort study
Hormone receptor
Internal medicine
patient characteristics
Oncology
early breast cancer
Adjuvant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations